What Is Semax? Research Evidence & Profile

What Is Semax?

Semax is a synthetic peptide research entry commonly discussed in neuropeptide literature. This page identifies the material as Semax, with amino acid count 7; synonyms Semax. The Semax identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Evidence at a Glance

0ClinicalTrials.gov query records

208PubMed query records

6Selected publications shown

Sources: ClinicalTrials.gov query · PubMed query · Retrieved 2026-10-06

Mechanism & Pharmacology

The research record for Semax is organized around neuropeptide characterization, peptide-signaling literature, signal-response studies, and analytical peptide workflows. For Semax, those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Mechanistic or pathway language defines a research scope. It does not establish that a catalogue product produces a clinical effect.

Clinical Development

Selected exact-query registry records are shown below. Desktop displays up to six; mobile displays up to three.

NCT ID / Study	Phase	Status	Context	Last registry update
No exact-match registry records were returned by the displayed query at the retrieval time.

Source: ClinicalTrials.gov search · Retrieved 2026-10-06

Selected Literature6 important records shown

Selected Literature

Selected PubMed record

Functional Connectomic Approach to Studying Selank and Semax Effects.

Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections · 2020 Jan

PMID 32342318

Selected PubMed record

Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.

British journal of pharmacology · 2025 Nov

PMID 40692165

Selected PubMed record

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026 Jan 1

PMID 41490200

Selected PubMed record

Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats.

Neuropeptides · 2021 Apr

PMID 33418449

Selected PubMed record

Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models.

ACS chemical neuroscience · 2022 Feb 16

PMID 35080861

Selected PubMed record

Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

Frontiers in aging · 2026

PMID 42021992

Source: PubMed search results · Retrieved 2026-10-06

Identity & ChemistryProduct-form fields

Identity & Chemistry

Compound / Blend: Semax
Available Specifications: 5mg, 10mg
Pack Format: 10 Vials
CAS Number: 80714-61-0
Molecular Formula: C37H51N9O10S
Molecular Weight: 813.93 g/mol
Amino Acid Count: 7
Sequence: Met-Glu-His-Phe-Pro-Gly-Pro
Synonyms: Semax
Physical Form: Lyophilized powder

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Source: PubChem CID 9811102 · Product form must still be matched to the catalogue and batch record.

Research Tools for Semax

Review the selected registry records and open the module-level ClinicalTrials.gov query for the current result set.

Open Clinical Development

Use the complete NOVABIO documentation library to review currently available batch records.

Open Lab Results & COA

Storage & Laboratory HandlingDocumentation-led controls

Storage & Laboratory Handling

Confirm the exact material form, lot, supplied state and storage statement from the product label and corresponding batch documentation. Do not infer handling conditions from a different compound, strength or external clinical publication.

Regulatory Status

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Source: FDA Drugs@FDA · Checked 2026-10-06

Authoritative Data Summary

Semax Research Summary

Identity

Semax; specifications: 5mg, 10mg. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Mechanism

Evidence

0 registry records and 208 PubMed records were returned by the displayed query on 2026-10-06; counts are not quality ratings.

Regulatory context

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Semax is represented here by the catalogue identity Semax. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation. The product record lists 5mg, 10mg as the currently available specifications. The research context is organized around this product-specific scope: The research record for Semax is organized around neuropeptide characterization, peptide-signaling literature, signal-response studies, and analytical peptide workflows. For Semax, those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome. The synchronized searches returned 0 ClinicalTrials.gov records and 208 PubMed records for the displayed query. A registry count includes records with different designs, statuses and populations, while a publication count can include reviews, preclinical work and unrelated uses of a shared abbreviation; neither count is a quality score. For regulatory interpretation, FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval. Clinical findings apply only to the studied drug product, formulation, population and protocol. NOVABIO product specifications and batch documentation are separate catalogue records and do not inherit clinical outcomes from external studies. This profile supports identity checking, source tracing and laboratory record review; it does not certify a batch, recommend treatment, provide dosing instructions or replace current official labeling and professional judgment.

Sources: PubMed · ClinicalTrials.gov · FDA · NOVABIO product record

FAQ4 evidence-bounded answers

Semax FAQ

What is Semax?

What research records are indexed for Semax?

The synchronized query returned 0 ClinicalTrials.gov records and 208 PubMed records on 2026-10-06; review the linked searches because counts and record status can change.

Is Semax FDA approved?

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Does this page provide dosing guidance?

No. This research profile provides identity, evidence, chemistry, regulatory and documentation context without dosing or treatment instructions.

Sources, Methodology & Last Verified

Official sources: ClinicalTrials.gov, NCBI PubMed, FDA, available PubChem records, and NOVABIO product and COA records.
Query retrieved: 2026-10-06T12:08:49Z
Inclusion: Exact identity terms and traceable registry, publication, chemistry, regulatory or catalogue fields.
Limitations: Search counts can include mixed evidence types and shared-name records; individual records require direct review.
Prepared by: NOVABIO Research
Reviewed date: 2026-10-06
Editorial methodology: How NOVABIO builds Research Profiles
Corrections contact: Contact NOVABIO with the page URL and source record.